Publications by authors named "A Osterborg"
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFBackground/objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor) antagonist (KAND567) on autologous monocytes and their pro-survival effects on CLL cells in vitro.
Methods: Plasma concentration of CX3CL1 was determined by ELISA and CX3CR1 expression by flow cytometry.
Background: It is thought that patients with inborn errors of immunity (IEI) are more susceptible to severe coronavirus disease 2019 (COVID-19) than the general population, but a quantification of this potential risk is largely missing.
Objective: We assessed the impact of COVID-19 on patients with IEI.
Methods: A nationwide cohort study was performed to estimate the relative risk (RR) for hospitalization, intensive care, and death within 30 days after a positive severe acute respiratory syndrome coronavirus 2 test result in an IEI population (n = 2392) compared to the general population (n = 8,270,705) using data from Swedish national registries.
Article Synopsis
- Immunocompromised patients have shown weak responses to initial SARS-CoV-2 mRNA vaccinations, prompting recommendations for extra booster doses; however, real-world data on these recommendations is limited.
- A two-year follow-up of the COVAXID clinical trial involved 364 participants, focusing on their immune responses and the effects of their vaccination schedule and underlying health conditions.
- The study found that while some patients who initially had poor responses improved after additional doses, their immune response remained affected by their immunosuppressive status, emphasizing the need for ongoing vaccination efforts in these populations.
Background: Data on the outcomes of COVID-19 in people living with HIV (PLHIV), specifically in relation to vaccination status, are lacking during the Omicron era.
Methods: This nationwide registry-based study included all resident in Sweden ≥18 years with a positive SARS-CoV-2 PCR test during January 2021-February 2023. We estimated adjusted odds ratios (adjOR) for COVID-19 hospitalisation and severe COVID-19 (ICU admission and 90-day mortality), categorised by SARS-CoV-2 vaccination status (0-1, 2, and ≥3 doses), and HIV-status.